Takeda Cements Norovirus Lead Through Vaccine Trial Start
This article was originally published in PharmAsia News
Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.
You may also be interested in...
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.